Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nelivaptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B known ✓ | P47901 | 20/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 11/20 | 1.00 |
| ▸ | OXTR | P30559 | 11/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 3/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nelivaptan SCHEMBL5349223 | 1.00 | AVPR1B (1.00) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| Nelivaptan SCHEMBL14517029 | 1.00 | AVPR1B (1.00) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| Nelivaptan SCHEMBL4307280 | 1.00 | AVPR1B (1.00) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| Nelivaptan SCHEMBL29380118 | 1.00 | AVPR1B (1.00) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| Nelivaptan SCHEMBL31317579 | 0.97 | AVPR1B (0.95) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5351446 | 0.95 | AVPR1B (0.91) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5347025 | 0.95 | AVPR1B (0.90) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7403029 | 0.95 | AVPR1B (0.90) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7408252 | 0.95 | AVPR1B (0.90) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5351285 | 0.95 | AVPR1B (0.90) | AVPR1BAVPR1AOXTRAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297692-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | claimed |
| US-7202267-B2 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | SANOFI-AVENTIS (FR) | 2007-04-10 | — | — | US | claimed |
| US-20070004703-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2007-01-04 | — | — | US | claimed |
| EP-1525198-B1 | ACYLOXYPYRROLIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2005-12-07 | — | — | EP | claimed |
| US-20050192335-A1 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | US | claimed |
| US-20050165082-A1 | Methods of treating vasomotor symptoms | WYETH (US) | 2005-07-28 | — | — | US | claimed |
| EP-1525198-A2 | ACYLOXYPYRROLIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-04-27 | — | — | EP | claimed |
| EP-1255751-B1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND THEIR USE AS LIGANDS FOR V1B OR V1B AND V1A ARGININE-VASOPRESSIN RECEPTORS | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-6730695-B2 | TREATMENT OF HYPERTENSION, CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-05-04 | — | — | US | claimed |
| WO-2004009585-A2 | ACYLOXYPYRROLIDINE DERIVATIVES AND USE THEREOF AS LIGANDS OF V1B OR BOTH V1B AND V1A RECEPTORS | SANOFI-AVENTIS (FR) | 2004-01-29 | — | — | WO | claimed |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | SANOFI (FR) | 2003-06-19 | — | — | US | claimed |
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11033601-B2 | Selective inhibition of V1b for treating fatty liver | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3623483-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-18 | — | — | EP | disclosed |
| US-20190083568-A1 | SELECTIVE INHIBITION OF V1b AND/OR STABILIZATION OR UPREGULATION OF V1a FOR TREATING FATTY LIVER | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY COPORATE | 2019-03-21 | — | — | US | disclosed |
| EP-1525198-A2 | ACYLOXYPYRROLIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI (FR) | 2004-10-21 | — | — | US | disclosed |
| US-6730695-B2 | TREATMENT OF HYPERTENSION, CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-05-04 | — | — | US | disclosed |
| WO-2004009585-A2 | ACYLOXYPYRROLIDINE DERIVATIVES AND USE THEREOF AS LIGANDS OF V1B OR BOTH V1B AND V1A RECEPTORS | SANOFI-AVENTIS (FR) | 2004-01-29 | — | — | WO | disclosed |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | AVPR1B, AVPR1A, AVPR2 | AVPR1B 1/4885AVPR1A 2/4885OXTR 7/4885 |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885AVPR1A 3/4885OXTR 16/4885 |
| US-20070004703-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVPR1B, AVPR2, AVPR1A | AVPR1B 1/4885AVPR1A 3/4885OXTR 6/4885 |
| US-20050192335-A1 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | HCAR3, MC2R, NPR3 | AVPR1B 101/4885AVPR1A 128/4885OXTR 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.